Novavax Inc Revenue Growth Rates (NVAX), Current and Historic Growth - CSIMarket
CSIMarket
 


Novavax inc   (NASDAQ: NVAX)
 

NVAX's Revenue Growth by Quarter and Year

Novavax Inc 's Revenue results by quarter and year




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/NVAX/growth
https://api.csimarket.com/api/v1/companies/NVAX/fundamentals
https://api.csimarket.com/api/v1/companies/NVAX/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
NVAX Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 68.30
2nd Quarter June 56.70
1st Quarter March 139.51
FY 264.51

NVAXs Annual Revenue
Novavax Inc 's Revenue in the fiscal year 2025 $ 1,123.48 millions
Novavax Inc 's Revenue in the fiscal year 2024 $ 682.16 millions
Novavax Inc 's Revenue in the fiscal year 2023 $ 983.71 millions
Novavax Inc 's Revenue in the fiscal year 2022 $ 1,981.87 millions
Novavax Inc 's Revenue in the fiscal year 2021 $ 1,146.29 millions




NVAX Revenue third quarter 2026 Y/Y Growth Comment
Novavax Inc reported decrease in Revenue in the third quarter 2026 by -3.05% to $ 68.30 millions, from the same quarter in 2025.
The decrease in the third quarter 2026 Novavax Inc 's Revenue compares unfavorably to the Company's average Revenue doubling of 216.95%.

Looking into third quarter 2026 results within Biotechnology & Pharmaceuticals industry 47 other companies have achieved higher Revenue growth. While Novavax Inc ' s Revenue decline of -3.05% ranks overall at the positon no. 3310 in the third quarter 2026.




NVAX Revenue ( Y/Y Growth %) 2026
FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -3.05 %
2nd Quarter June -76.3 %
1st Quarter March -79.07 %
FY   -

Financial Statements
Novavax Inc 's third quarter 2026 Revenue $ 68.30 millions NVAX's Income Statement
Novavax Inc 's third quarter 2025 Revenue $ 70.45 millions Quarterly NVAX's Income Statement


NVAX Revenue (Quarter on Quarter Growth %)

2026
FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 20.46 %
2nd Quarter June -59.36 %
1st Quarter March -5.19 %
FY (Year on Year)   -




Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #48
Healthcare Sector #440
Overall #3310

Revenue Y/Y Growth Statistics
High Average Low
4991.93 % 216.95 % -61.64 %
(Mar 31 2021)   (Jun 30 2026)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #48
Healthcare Sector #440
Overall #3310
Revenue Y/Y Growth Statistics
High Average Low
4991.93 % 216.95 % -61.64 %
(Mar 31 2021)   (Jun 30 2026)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Novavax Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
952.35 % 57.1 % -79.66 %
(Jun 30 2020)  


NVAX's III. Quarter Q/Q Revenue Comment
Novavax inc achieved in the III. Quarter 2026 below company average Revenue jump of 20.46% quarter on quarter, to $ 68.30 millions.

Although the III. Quarter 2026 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the III. Quarter surge, eclipses the -70.55% growth in the III. Quarter a year ago

Within Biotechnology & Pharmaceuticals industry 57 other companies have achieved higher Revenue quarter on quarter growth. While Novavax Inc 's Revenue growth quarter on quarter, overall rank is 3736.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #58
Healthcare Sector #544
Overall #3736
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #58
Healthcare Sector #544
Overall #3736
Revenue Q/Q Growth Statistics
High Average Low
952.35 % 57.1 % -79.66 %
(Jun 30 2020)  


NVAX's III. Quarter Q/Q Revenue Comment
Novavax inc achieved in the III. Quarter 2026 below company average Revenue jump of 20.46% quarter on quarter, to $ 68.30 millions.

III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -70.55% in the III. Quarter a year ago.

Within Biotechnology & Pharmaceuticals industry 57 other companies have achieved higher Revenue quarter on quarter growth. While Novavax Inc 's Revenue growth quarter on quarter, overall rank is 3736.


Novavax Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)
12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 411.65
Y / Y Revenue Growth (TTM) -61.33 %
Year on Year Revenue Growth Overall Ranking # 1605
Seqeuential Revenue Change (TTM) -0.52 %
Seq. Revenue Growth (TTM) Overall Ranking # 3310


Cumulative Revenue growth Comment
Novavax Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Jun 30 2026. If the fiscal year would end in Sep 30 2026, Novavax Inc 's annual Revenue decline would be -61.33% year on year to $412 millions.

In the Healthcare sector 259 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 142 to 1605.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 48
Healthcare Sector # 260
Overall # 1605

Revenue TTM Y/Y Growth Statistics
High Average Low
4991.93 %
216.95 %
-61.64 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 48
Sector # 440
S&P 500 # 3310
Cumulative Revenue growth Comment
Novavax Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Jun 30 2026. If the fiscal year would end in Sep 30 2026, Novavax Inc 's annual Revenue drop would be -61.33% year on year to $412 millions.

In the Healthcare sector 259 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 142 to 1605.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 48
Healthcare Sector # 260
Overall # 1605

Revenue TTM Y/Y Growth Statistics
High Average Low
4991.93 %
216.95 %
-61.64 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 48
Sector # 440
S&P 500 # 3310




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
NVAX's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue drop for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Nuwellis Inc -0.23%$ -0.226 millions
Viatris Inc -0.28%$ -0.277 millions
Zoetis Inc -0.38%$ -0.375 millions
Pfizer Inc-0.43%$ -0.426 millions
Standard Biotools Inc -0.51%$ -0.508 millions
Lucid Diagnostics Inc -0.66%$ -0.661 millions
Globus Medical Inc -0.69%$ -0.693 millions
Conmed Corporation-0.70%$ -0.701 millions
Surgery Partners Inc -0.75%$ -0.755 millions
Myriad Genetics Inc -1.03%$ -1.025 millions
Lensar Inc -1.29%$ -1.292 millions
Fortrea Holdings Inc -1.40%$ -1.397 millions
Immunocore Holdings Plc-1.42%$ -1.419 millions
Pacira Biosciences inc -1.59%$ -1.595 millions
Organon and Co -1.75%$ -1.748 millions
Teva Pharmaceutical Industries Limited-1.90%$ -1.897 millions
Skinhealth Systems Inc -2.07%$ -2.071 millions
Charles River Laboratories International inc -2.20%$ -2.201 millions
Inogen Inc -2.40%$ -2.399 millions
Novavax inc -3.05%$ -3.048 millions
Seer Inc -3.14%$ -3.139 millions
Teladoc Health Inc -3.41%$ -3.406 millions
Scientific Industries Inc -3.50%$ -3.504 millions
Cg Oncology Inc -3.72%$ -3.721 millions
Treace Medical Concepts Inc -3.91%$ -3.905 millions
Sarepta Therapeutics Inc -4.51%$ -4.509 millions
Pacific Health Care Organization Inc-4.69%$ -4.689 millions
Tela Bio Inc -5.06%$ -5.058 millions
Perrigo Company Plc-5.22%$ -5.225 millions
Heron Therapeutics Inc -5.49%$ -5.493 millions


About Novavax Inc Revenue Growth Rates (NVAX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Novavax Inc (CIK 1000694).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001000694-26-000022
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Novavax Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.